Tag: Needham
-
Here’s Why Rocket Pharma Blasted 37% Higher
Rocket Pharmaceuticals (RCKT) is blasting off. All after the company reached an “alignment” with the U.S. FDA over its mid-stage trial design for its Danon disease therapy, RP-A501, for which there are no US FDA-approved treatments. As noted by Barron’s, “The pharmaceutical company said Tuesday that it had reached an agreement with the FDA to…
-
Okta About to Refill its Bearish Gap
On March 2, we noted, “Keep an eye on Okta (OKTA). After Cowen analysts upgraded the stock to an outperform rating from market perform, with a $70 price target, the stock took off. Since the start of 2023, OKTA ran from about $60 to $81 so far. From here, we’d like to see it initially…
-
Weakness is an Opportunity with Roblox Corp.
Keep an eye on Roblox Corp. (RBLX). One, after gapping lower on disappointing monthly user growth and booking metrics, the stock appears to have bottomed out. Not only did RBLX catch double bottom support, it’s starting to pivot from oversold reads on RSI, MACD, and Williams’ %R. Two, RBLX is the closest thing to a…